Type 2 Diabetes Trial, Recruiting NCT05776563 Sponsor: Yale University Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT05776563
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form agreeing to take part in the study
  • You are able to commit to following all study procedures for the full length of the study
  • You are male or female, between 18 and 60 years old
  • You have a diagnosis of Type 2 diabetes in your medical history
  • Your blood sugar control (HbA1c) is above 7.5% and your body mass index (BMI) is 18 or above
  • You are willing to make changes to your diabetes treatment plan as part of the study

Who may not be able to join:

  • Your kidney function blood test (creatinine) result is above 1.5 mg/dL
  • Your blood count is too low — specifically, low haemoglobin (below 10 mg/dL) or low haematocrit (below 37% for men or below 33% for women)
  • Your liver enzyme levels (ALT) are more than 3 times the normal upper limit
  • You have a thyroid condition that is not currently being treated
  • You have high blood pressure that is not well controlled
  • You have a known neurological (brain or nerve) condition
  • You have a psychiatric (mental health) condition that is not currently being treated
  • You have or have had cancer
  • You have a condition that affects blood clotting or causes excessive bleeding
  • You have used steroid medications in the last 3 months
  • You currently use illegal drugs
  • For women: you are pregnant, trying to become pregnant, or currently breastfeeding
  • You are unable to safely have an MRI scan (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Elizabeth Sanchez Rangel, MD, Yale University

Phone: 203-785-6430

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
19 July 2024
Est. completion
31 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Brain glucose concentration in the occipital cortex week 0; Brain glucose concentration in the occipital cortex week 12

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov